Bringing you the latest Business News updates from the science industry
by Heather Hobbs Queen’s Award for NanoSight
Nanoparticle characterisation technology manufacturer NanoSight has been selected to receive the Queen's Award for Enterprise - Innovation in 2013.
The company was founded in 2004 by Dr Bob Carr and John Knowles, after Carr discovered a technology which allows particles, small enough to be below the resolution limit of normal optical microscopes, to be visualised, sized and counted without the need for an electron microscope.
Mrs Sarah Troughton, Lord-Lieutenant of Wiltshire, presenting NanoSight CTO, Bob Carr, with the Queen's Award for Enterprise: International Trade 2012
Since 2005, NanoSight has grown sales by more than 60% annually, year on year, and now employs 47 people worldwide. The most significant growth has been in pharmaceuticals and life sciences, where budgets have remained largely unaffected by the
global financial condition, the company said. There are now more than 600 NanoSight instruments in use worldwide, with the firm’s products having been cited in academic papers said to total over 700.
Speaking about the importance of this award, Dr Carr said "Winning this award is further recognition of our Nanoparticle Tracking Analysis (NTA) technique as an outstanding technology to meet the needs of the burgeoning nanomaterials sector. It is reward to our team at Salisbury who continue to innovate both hardware and software improvements to meet the challenging demands of our users."
The company also received a 2012 Queen's Award for Enterprise - International Trade.
MORE INFO. 43 Irish Venture to Deliver Biodegradable Implants
A consortium of three Irish biomedical companies - Venn Life Sciences Holdings Plc, Cellulac Ltd and Biopharmed West Ltd have announce a joint venture to pursue the development of biodegradable human implants. The joint venture provides a complement of expertise beginning at traceability and processing of raw materials to finished medical grade PolyLactic Acid, (PLA), a component in the manufacture of implanted medical devices in the operating theatre. Product range is potentially from
internal sutures to orthopaedic bone regeneration implants providing a clean technological solution for the replacing of titanium.
Venn Life Sciences is to provide clinical trial management and resourcing solutions to pharmaceutical, biotechnology and medical device clients. Cellulac Ltd, currently involved in a major EU project involving potential uses of biobased chemicals from lignocellulose and alga, will provide
the scientific laboratories, production and clean room infrastructure, quality controls and access to its portfolio of patents in the production of biodegradable PLA. Partners in this project include Fraunhofer Institiute, Nova Institute and Wageningen University.
Biopharmed West Ltd will contribute institutional, commercial know-how and management of distribution channels
MORE INFO. 44 Novasep Redefines Safety Properties of Reagent
Research scientists at Novasep, a leading supplier of synthetic molecules and biomolecules, recently discovered and characterised the explosive properties of the Togni reagent II and intermediates at the company’s Leverkusen site in Germany. Togni reagent II (1-(trifluoromethyl)-1,2- benziodoxol-3(1H)-one, 1) is a versatile reagent for the electrophilic introduction of trifluoromethyl groups. It is used in pharmaceutical manufacturing and also widely used in universities.
Authorised by the German Government to handle energetic materials and operate hazardous reactions
from lab to thousands tons scale, Novasep conducted a Koenen test on a sample of Togni Reagent II prepared in their kilolab, in which the reagent was shown to be highly explosive. Another critical property of the Togni Reagent II clarified by the Novasep team is its fast combustion when ignited. The combustion factor was measured as BZ6, the same classification as black powder.
This discovery has resulted in a revised classification for handling and transportation of the Togni reagent II, which must now be approved by national competent authorities. Novasep has also informed companies
known to market the compound, who will relay the safety measures required to handle the reagent.
“The work completed by Novasep regarding the Togni Reagent II will contribute to a more deliberate and responsible handling of the reagent used by so many research groups," said Professor Togni, professor of organometallic chemistry at the Laboratory of Inorganic Chemistry, ETH Zurich and inventor of the reagent.
The findings were published in the March edition of the journal Organic Process Research and Development.
MORE INFO. 45
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48 |
Page 49 |
Page 50 |
Page 51 |
Page 52 |
Page 53 |
Page 54 |
Page 55 |
Page 56 |
Page 57 |
Page 58 |
Page 59 |
Page 60 |
Page 61 |
Page 62 |
Page 63 |
Page 64 |
Page 65 |
Page 66 |
Page 67 |
Page 68 |
Page 69 |
Page 70 |
Page 71 |
Page 72 |
Page 73 |
Page 74 |
Page 75 |
Page 76 |
Page 77 |
Page 78 |
Page 79 |
Page 80 |
Page 81 |
Page 82 |
Page 83 |
Page 84 |
Page 85 |
Page 86 |
Page 87 |
Page 88 |
Page 89 |
Page 90 |
Page 91 |
Page 92 |
Page 93 |
Page 94 |
Page 95 |
Page 96 |
Page 97 |
Page 98 |
Page 99 |
Page 100 |
Page 101 |
Page 102 |
Page 103 |
Page 104 |
Page 105 |
Page 106 |
Page 107 |
Page 108 |
Page 109 |
Page 110 |
Page 111 |
Page 112 |
Page 113 |
Page 114 |
Page 115 |
Page 116 |
Page 117 |
Page 118 |
Page 119 |
Page 120 |
Page 121 |
Page 122 |
Page 123 |
Page 124 |
Page 125 |
Page 126 |
Page 127 |
Page 128 |
Page 129 |
Page 130 |
Page 131 |
Page 132 |
Page 133 |
Page 134 |
Page 135 |
Page 136 |
Page 137 |
Page 138 |
Page 139 |
Page 140 |
Page 141 |
Page 142 |
Page 143 |
Page 144 |
Page 145 |
Page 146 |
Page 147 |
Page 148 |
Page 149 |
Page 150 |
Page 151 |
Page 152 |
Page 153 |
Page 154 |
Page 155 |
Page 156 |
Page 157 |
Page 158 |
Page 159 |
Page 160 |
Page 161 |
Page 162 |
Page 163 |
Page 164 |
Page 165 |
Page 166 |
Page 167 |
Page 168 |
Page 169 |
Page 170 |
Page 171 |
Page 172 |
Page 173 |
Page 174 |
Page 175 |
Page 176 |
Page 177 |
Page 178 |
Page 179 |
Page 180 |
Page 181 |
Page 182 |
Page 183 |
Page 184 |
Page 185 |
Page 186 |
Page 187 |
Page 188 |
Page 189 |
Page 190 |
Page 191 |
Page 192 |
Page 193 |
Page 194 |
Page 195 |
Page 196 |
Page 197 |
Page 198 |
Page 199 |
Page 200 |
Page 201 |
Page 202 |
Page 203 |
Page 204 |
Page 205 |
Page 206 |
Page 207 |
Page 208 |
Page 209 |
Page 210 |
Page 211 |
Page 212 |
Page 213 |
Page 214 |
Page 215 |
Page 216 |
Page 217 |
Page 218 |
Page 219 |
Page 220 |
Page 221 |
Page 222
